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ABSTRACT
Introduction Psychosocial interventions for patients with 
breast cancer (BC) have demonstrated their effectiveness 
at reducing emotional distress and improving quality 
of life. The current digitisation of screening, monitoring 
and psychosocial treatment presents the opportunity 
for a revolution that could improve the quality of care 
and reduce its economic burden. The objectives of this 
study are, first, to assess the effectiveness of an e- health 
platform with integrated and stepped psychosocial 
services compared with usual psychosocial care, and 
second, to examine its cost–utility.
Methods and analysis This study is a multicentre 
randomised controlled trial with two parallel groups: 
E- health intervention with integrated and stepped 
psychosocial services vs usual psychosocial care. An 
estimated sample of 338 patients with BC in the acute 
survival phase will be recruited from three university 
hospitals in Catalonia (Spain) and will be randomly 
assigned to one of two groups. All participants will be 
evaluated at the beginning of the study (T1: recruitment), 
3 months from T1 (T2), 6 months from T1 (T3) and 12 
months from T1 (T4). Primary outcome measures will 
include number of clinical cases detected, waiting time 
from detection to psychosocial intervention and proportion 
of cases successfully treated in the different steps of the 
intervention, as well as outcomes related to emotional 
distress, quality of life, post- traumatic stress and growth, 
treatment adherence and therapeutic alliance. Secondary 
outcomes will include the acceptability of the platform, 
patients’ satisfaction and usability. For the cost–utility 
analysis, we will assess quality- adjusted life years and 
costs related to healthcare utilisation, medication use and 
adherence, work absenteeism and infrastructure- related 
and transport- related costs.
Ethics and dissemination This study was approved 
by the Ethics committee of the Institut Català 
d’Oncologia network in Hospitalet, Spain. Findings will 
be disseminated through peer- reviewed journals, reports 
to the funding body, conferences among the scientific 
community, workshops with patients and media press 
releases.
Trial registration number Online Psychosocial Cancer 
Screening, Monitoring and Stepped Treatment in Cancer 
Survivors (ICOnnectat- B),NCT04372459.
BACKGROUND
It is estimated that there are currently over 
100 million cancer survivors worldwide, a 
number that is constantly increasing.1 More 
specifically, according to the Spanish Society 
of Medical Oncology,2 one in eight women in 
Spain will present breast cancer (BC) at some 
point in their lives, a disease that has a 5- year 
relative survival rate of 89.2%. However, an 
increase in survival rates does not necessarily 
imply greater well- being, since several studies 
have shown that cancer diagnosis and its treat-
ment cause physical limitations, psychosocial 
problems, work- related challenges and poor 
quality of life among survivors.3 4 In particular, 
psychological distress is found among almost 
40% of individuals who have gone through 
an oncological process5 and evidence shows 
that when it is treated adequately, it is asso-
ciated with better health outcomes and 
higher survival rates.6 7 However, only a small 
proportion of survivors is currently screened 
Strengths and limitations of this study
 ► The sample size was calculated taking into account 
the high dropout rate commonly reported in e- health 
interventions; to deal adequately with this limitation, 
an extra 25% of patients will be recruited.
 ► The study focuses on the specific group of patients 
with BC and consequently difficulties may be en-
countered in generalising results to other cancer 
populations.
 ► This trial is designed as a multicentre study and 
uses a rigorous methodology.
 ► Collecting data on healthcare utilisation and its costs 
and work absenteeism at different time points will 
allow a comprehensive economic evaluation of the 
e- health intervention.
 ► Intention- to- treat analyses will be performed using 
linear mixed models to examine the longitudinal 
changes of participants according to their assigned 
treatment group.
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and referred to the proper health professionals to receive 
psychosocial care, and the waiting time to receive such 
treatment is often long; for example, workload and time 
constraints have been mentioned as important barriers to 
treatment delivery by health professionals.8
In recent years, e- health has emerged as an innovative 
resource to expand the availability and reach of psycho-
logical treatments for cancer survivors. At the same 
time, e- health has been able to mitigate concerns about 
anonymity and barriers associated with long waiting lists 
at hospitals or work, and time and mobility restrictions. 
The benefits of e- health in promoting change in health- 
related behaviours and knowledge, as well as in quality 
of life and other clinical outcomes, have been well docu-
mented in the literature.9–11 Specifically, there is empirical 
evidence examining the effectiveness of the indepen-
dent use of web- based platforms for stress management, 
coping and behavioural monitoring in BC,12–14 online 
educational platforms15–17 and online support groups.18–21 
However, evidence- based e- health interventions specifi-
cally designed for patients with BC that offer personalised 
and stepped interventions adapted to patients’ needs are 
lacking, as are studies assessing their clinical efficacy, cost- 
effectiveness and feasibility.10
In this context, the e- health unit and the psycho- 
oncology department of the Institut Català d’Oncologia 
(ICO) developed the programme ICOnnecta’t.22 This 
programme is the first innovative e- health ecosystem 
aimed at building online communication spaces and 
fostering healthy experiences among patients ith BC. The 
programme also integrates a psychosocial programme 
of four steps that are ranked according to patient 
complexity. This programme was initially implemented 
in 2019 in three centres of the ICO (Hospitalet, Badalona 
and Girona) (http:// ico. gencat. cat/ ca/ l_ institut/ 
centres/) and 6 months later it was expanded in Europe 
(Instituto Português de Oncologia de Coimbra, Portugal, 
and Szpital Mikolaja Kopernika w Łodzi, Poland) with the 
name ‘ONCOMMUN’ (https:// oncommun. eu), a project 
supported by the prestigious European Institute of Inno-
vation and Technology. Since 2020, the project has been 
implemented at two more Spanish institutions (Hospital 
General Universitario Gregorio Marañón in Madrid, and 
Hospital de la Santa Creu i Sant Pau in Barcelona).
ICOnnecta’t guarantees the provision of the correct 
screening, monitoring and support in health education, 
and adherence to treatments, and provides emotional 
and psychosocial support during the different transi-
tions that take place in the oncological process, through 
evidence- based, stepped and integrated services. The first 
level of care of ICOnnecta’t is an online screening and 
monitoring tool (level 1), followed by a cancer survivors’ 
campus with online educational resources to increase 
knowledge about the disease (level 2), a psychosocial 
support community where patients and professionals can 
interact, in the form of a private social network (level 3) 
and a psycho- oncological group treatment through video-
conference (level 4).
The purpose of this study is to conduct a multicentre 
randomised controlled trial (RCT) with an estimated 
sample of 338 patients with BC. In this RCT, partici-
pants in the experimental group will use the e- health 
ecosystem ICOnnecta’t, while those in the control group 
will follow the usual psychosocial treatment (ie, one indi-
vidual 1- hour session with a clinical psychologist every 
month). Then, effectiveness and cost–utility analyses will 
be performed. To this end, we have the following specific 
objectives:
 ► To examine the effectiveness of the e- health platform 
compared with usual psychosocial care in terms of: 
(1) waiting time for detection, delivery of psychoso-
cial care and resolution of clinical cases, (2) change in 
psychological variables including emotional distress, 
post- traumatic stress and growth, therapeutic alliance 
and quality of life and (3) users’ satisfaction with the 
platform and its usability.
 ► To compare the cost–utility balance between the 
e- health platform and the usual psychosocial care in 
terms of QALYs, time lapse for return- to- work, phar-
macological adherence and healthcare utilisation 
with all the related costs.
The implementation of the online intervention 
programme is expected to result in a significant improve-
ment in the primary and secondary outcome measures 
compared with the control group. More specifically:
 ► The e- health platform should lead to significantly 
greater improvements (differences between T1 and 
T2, which should also be maintained at T3 and T4) in 
the primary outcome variables, including waiting time 
for detection, intervention and resolution of mild and 
moderate clinical cases as well as emotional distress, 
post- traumatic stress and growth, therapeutic alliance 
and quality of life, in comparison to usual care.
 ► The e- health intervention should prove to be more 
cost- effective compared with usual care in terms of 
QALYs, pharmacological adherence, work absen-
teeism and costs related to healthcare utilisation.
 ► The e- health platform should show satisfactory levels 
of acceptability and usability by users.
METHODS AND ANALYSIS
Design
The study proposes a multicentre superiority RCT with two 
parallel groups (online integrated and stepped psychoso-
cial care vs usual psychosocial care) with 1:1 allocation. 
The study design will contain 2 (treatment conditions) 
× 4 (follow- up assessments) factors. The Consolidated 
Standards of Reporting Trials 2010 statement: extension 
to pilot and feasibility trials has been followed in the plan-
ning of the study and reporting of the protocol.23
Patient and public involvement
The study follows a responsible research and innova-
tion approach, according to which the research ques-
tion was shared, coconstructed and informed to our 
cancer patient committee and collaborating non- profit 
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cancer associations. Patients were actively involved in the 
design of the ecosystem through cocreation/codevelop-
ment activities. Patients will be indirectly involved in the 
recruitment, informing and encouraging other patients 
to participate. Finally, results will be disseminated to study 
participants and general public through citizen engage-
ment meetings.
Sample
The total sample will be approximately 338 patients with 
a diagnosis of BC during the acute survival phase (from 
6 weeks’ postdiagnosis until the end of primary oncolog-
ical treatment) from three centres of the ICO network 
in Catalonia (Hospital Duran i Reynals in Hospitalet, 
Hospital Germans Trias i Pujol in Badalona and Hospital 
Josep Trueta in Girona).
Inclusion criteria
1. Patients aged ≥18 years with BC, within 6 weeks after 
diagnosis.
2. Having online access and a user- level knowledge of the 
internet.
3. Understanding of Spanish language.
Exclusion criteria
1. Major depressive episode.
2. Significant autolytic ideation.
3. Showing symptoms of psychosis or substance abuse.
4. Intellectual disability or any major illness seriously af-
fecting their cognitive performance (eg, neurological 
disorders).
Considerations for access to the internet for the experi-
mental group only: It will be mandatory to have access to 
the internet using a proper terminal (eg, mobile, tablet 
or personal computer) that meets the minimum require-
ments to participate in the study. This includes access to 
the terminal in a private place and having a microphone 
and a webcam. We will lend a webcam, a microphone, or 
a tablet to those patients who do not have these resources. 
This first- stage contact with patients constitutes a brief 
digital reception focused only on the installation of the 
App and a little road trip (5 min) in its interface and 
dynamics, avoiding any potential digital, educational or 
psychosocial empowering which could be a cofounder.
Procedure and randomisation
All material with information related to the study (research 
protocol, informed consent, patient information sheet) 
has been approved by the Ethics committee headquarters 
of the ICO network in Hospitalet (PR289/19).
Participants will be recruited in the oncology and radio-
therapy services of the three participating hospitals, with 
variation in the number of recruited patients depending 
on each hospital’s care volume.
Selection and invitation to participate in the study will 
take place when the patients first visit the nursing staff 
assigned to them, immediately after visiting their oncolo-
gist, at which point the diagnosis and care plan will have 
been shared with them. The nurse will introduce the study 
and explain its objectives. Next, for women interested in 
taking part in the study, face- to- face meetings with psychol-
ogists in our research team will take place, in which the 
inclusion criteria will be verified through a brief inter-
view, the study objectives will be presented and the written 
informed consent will be signed in the case of acceptance. 
Then, a randomisation procedure will take place to assign 
the treatment groups (experimental or control group). 
This randomisation will be carried out through a list of 
randomly generated numbers on a computer system using 
IBM SPSS V.24 software24 by an independent researcher 
blind to the research questions and treatment conditions. 
The psychologist carrying out the recruitment interview will 
be responsible for communicating the assignment of the 
study group. Given the nature of both treatment modali-
ties, neither patients nor health professionals will be blind 
to intervention assignment.
Patients from the experimental group will be given oral 
and written instructions about the basic functioning of the 
e- health platform and the applications will be downloaded 
onto their mobile phones. In turn, patients from the control 
group will be told that a mental health professional at their 
institution will contact them to arrange the first face- to- face 
visit. Then, each group of patients will receive their corre-
sponding treatment for a period of 12 months.
All participants will be evaluated through online surveys 
at the beginning of the study (T1: recruitment), 3 months 
from T1 (T2), 6 months from T1 (T3) and 12 months 
from T1 (T4), regardless their assigned arm. However, only 
participants from the experimental group will be asked to 
complete the System Usability Scale (SUS) and the digital 
emotional state thermometer, since these are associated 
with the functionality of the e- health stepped programme. 
To optimise participant retention and complete follow- up, 
reminder mails will be sent to all participants at T2, T3 and 
T4. Finally, if a significant worsening on patient’s psycho-
logical well- being is identified during the whole procedure, 
a face- to- face visit with an expert in psycho- oncology of one 
of the ICO Hospitals will be scheduled for her, to assess 
whether or not she will have to discontinue her participa-
tion in the trial. Figure 1 presents the procedure and the 
timeline of the study and table 1 provides a detailed descrip-
tion of the methodology with a definition of the study vari-
ables and their assessment tools.
Study conditions and data collection
E-health ecosystem with integrated and stepped psychosocial 
services
Survivors allocated to this intervention will be monitored 
by the system for early detection of possible psychosocial 
needs, allowing the delivery of integrated and stepped 
care, when necessary. The programme ICOnnecta’t22 
features four levels, increasing in intensity of psycho-
social care as patients move from one level to the next. 
Members of the research team will coordinate the moni-
toring of patients through the e- health platform. Psychol-
ogists performing the online psychosocial interventions 
in the e- health platform will receive specific training.
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The four steps break down as follows:
Step 1: screening and monitoring
The screening and monitoring of several psychosocial 
variables will be carried out through the central mobile 
application of the programme (App ICOnnecta’t). 
Healthcare professionals will schedule alerts on their 
patients’ devices requesting them to complete specific 
questionnaires, and in this way, the evolution of their 
medication adherence (concomitant pharmacological 
treatment), emotional distress and well- being, among 
other health indicators (see table 1), as well as any spon-
taneously reported adverse event will be monitored 
on a regular basis. Likewise, patients will have at their 
disposal an encrypted messaging system to commu-
nicate adverse effects, abandonment or worsening of 
their mood to their healthcare professional. The indi-
cator for moving to the next and more intensive level of 
psychosocial care will be scores ≥6 (positive screening) 
on the emotional distress thermometer for two consec-
utive weeks. Women with positive screening results will 
be asked to answer a standardised instrument for the 
detection of clinical distress, the Hospital Anxiety and 
Depression Scale (HADS). Patients whose scores on this 
scale confirm clinical distress (HADS scores >10; positive 
monitoring) will be scaled up to the second level of care. 
The same procedure will be carried out for movements 
from the second to third level and from the third to 
fourth level, although participants will stay in each step 
for at least 2 weeks. It is worth declaring that the above- 
mentioned procedure is an adaptation of the stepped 
care programme for cancer patients described by Jansen 
et al.25 In addition, all movements between levels will 
be preceded by a videoconference with a psychologist 
in the research team to accompany and guide patients 
throughout the process.
Step 2: campus: psychoeducation and health education
The ICOnnecta’t Campus forms the second level of 
psychosocial care. This is an educational platform on 
Moodle via which patients can consult videos and online 
resources, co- constructed between health professionals 
and patients, containing reliable and rigorous informa-
tion related to the oncological process. This information 
will be divided into thematic blocks, each one describing 
challenges found at the different stages of the oncolog-
ical process, including emotions, medical treatments, 
personal relationships and healthy habits. After accessing 
each resource, users will be asked to complete a question-
naire to appraise the health knowledge acquired. The 
same questionnaire will be administered to participants 
in the control group.
Figure 1 Timeline and procedure.
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Table 1 Instruments for measuring clinical efficacy, cost- effectiveness and adherence to the online stepped intervention
Dimension Methodology Assessment measures T1
During treatment 
(weekly) T2 T3 T4
Clinical efficacy




 ► Age, working situation, marital status
 ► Current diagnosis and treatment, 
previous diagnosis and 
treatment, time since diagnosis, 
pharmacological treatment, history of 
physical or mental health illness
x         
  Emotional distress Online 
Questionnaire
Hospital Anxiety and Depression Scale 
(HADS)
x   x x x
  Post- traumatic dtress Online 
Questionnaire
Post- traumatic Stress Disorder 
Checklist
x   x x x
  Post- traumatic growth Online 
Questionnaire
Post- traumatic Growth Inventory x   x x x
  Therapeutic alliance Online 
Questionnaire
The Working Alliance Inventory     x x x
Cost–utility and cost- effectiveness analysis
  Quality of life Online 
Questionnaire
EuroQoL-EQ- 5D- 3L x   x x x
  Patient’s work absenteeism SAP N° of days of sick leaves         x
  Patient’s healthcare 
utilisation
SAP N° of visits to healthcare professionals         x




 ► Adherence to Refills and Medication 
Scale
 ► Daily record system for taking 
medication through App
 ► Consumption of psychotropic 
medication (SAP)
x   x x x
  Professionals’ salaries 
(psychologists, nursing 
staff)
SAP N° of the professionals involved in the 
online treatment or usual care, no of 
working hours per week and their costs
        x
  Infrastructure costs
 ►  Development and 
maintenance of the online 
platform (experimental 
group)
 ►  Hospital’s infrastructure 
(control group)
  Technological 
provider
  Hospital 
management
  Cost per user and month of the e- 
health platform
  Costs of hospital’s infrastructure per 
face- to- face visits per user and month
        x
  Transport costs Mobility data to 
receive care
Cost estimate per patient using a 
specific transport according to mobility 
data in our area
        x
Usability, adherence and follow- up of the online stepped intervention
  Emotional well- being * Online 
Questionnaire
Emotional thermometer (ET)—Visual 
Analogue Scale (VAS) (0–10)
  x       
  N° of clinical cases 
detected*
  N° of cases with HADS scores >10   If ET>5 and every 
3 months
      
  Waiting time to begin 
psychosocial intervention*
  Period of time from detection of a 
clinical case (HADS scores>10) to 
intervention enrolment
  If ET>5 and every 
3 months
      
  Percentage of resolved 
cases*
  N° of cases with HADS scores <10   If ET>5 and every 
3 months
      
Continued
 on M
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Step 3: psychosocial support community
If the patient does not improve within 2 weeks during 
step 2, she will be contacted by a psychologist from the 
research team through a videoconference and be offered 
the option to participate in the online community of 
psychosocial support for patients ith BC (App Comuni-
tats). This online community aims to create a digital ther-
apeutic alliance between patients, and between patients 
and health professionals. This community is anonymous 
and is supervised by a psycho- oncologist, an oncolog-
ical nurse and a BC survivor mentor with experience in 
the use and support of virtual communities. Specifically, 
through this private social network, participants can 
choose from 12 cancer- related discussion forums and 
share with the community any health- related question 
that worries them, thus fostering debate and stimulating 
peer- support.
Step 4: intensive online group psychotherapy
If the patient does not improve within 2 weeks during step 
3, she will be offered the option to participate in weekly 
group- based psychotherapy (App ICOnnecta’t Video-
consulta), which is based on the Group Positive Psycho-
therapy programme for cancer survivors26 27 and adapted 
for patients under primary oncological treatments. 
Group positive psychotherapy has been compared with 
a waiting- list control group in a previous study28 and to 
other evidence- based interventions29 and showed better 
results in terms of patients’ psychological well- being. 
This step will compromise 8 weekly 90 min sessions led 
by a clinical psychologist (an expert in psycho- oncology) 
with a follow- up 3 months later. In addition, patients will 
be offered an online appointment with a psychiatrist to 
assess the need for psychopharmacological treatment if 
emotional distress persists.
Psychosocial treatment as usual
This active control group will receive the standard 
psychosocial treatment for cancer survivors in the partic-
ipating centres, led by a clinical psychologist. In a recent 
agreement (2018) regarding the standard psychosocial 
treatment offered by the three participating hospitals, it 
was established that the average psycho- oncological treat-
ment offered consisted of 6–9 individual, 60 min sessions 
focused on emotional support and psychoeducation 
during the first year of primary cancer treatment. In 
order to be more systematic in the programme design 
and ensure homogeneous ‘treatment as usual’ in the 
three participating hospitals, all hospitals committed 
to carrying out 8 monthly psycho- oncological visits of 
45–60 min per participant.
Measurements
Clinical efficacy measures
Sociodemographic and clinical data will be obtained 
from the hospital’s electronic health record (Servicio de 
Atención al Paciente, SAP).
Emotional distress
The HADS30 is an instrument designed to detect the pres-
ence and severity of anxiety and depression in people with 
physical illnesses. It has been validated in Spanish among 
a sample of patients with cancer,31 and showed good 
reliability (α=0.82 and α=0.84 for anxiety and depres-
sion subscales, respectively). It consists of 14 items, 7 for 
anxiety and 7 for depression, rated on a four- point Likert 
scale (range 0–3), with the total score ranging from 0 to 
42. Higher scores indicate a greater level of distress.
Post-traumatic stress
The Post- traumatic Stress Disorder Checklist for Diag-
nostic and Statistical Manual of Mental Health Disorders 
(DSM- V) (PCL-5)32 is a 20- item self- report question-
naire designed to assess post- traumatic stress disorder, 
according to the DSM- V.33 The questionnaire demon-
strated high internal consistency (α=0.94) and good test–
retest reliability (r=0.82). The official Spanish translation 
of the instrument was provided by the National Center 
for Post- Traumatic Stress Disorder (https://www. ptsd. va. 
gov/).
Post-traumatic growth
The PTGI34 is a 21- item instrument that assesses positive 
changes experienced after a trauma. Its Spanish valida-
tion among cancer patients by Costa- Requena and Gil35 
showed excellent internal consistency (α=0.95). We also 
incorporate in our analysis of PTG, the new knowledge 
and methods to interpret the productive and illusory part 
of this potential therapeutic response.36–38
Dimension Methodology Assessment measures T1
During treatment 
(weekly) T2 T3 T4
  Health education Online 
Questionnaires
Scores on health education 
questionnaires
  Single 
measurement per 
topic
      
  Usability and satisfaction Online 
Questionnaires
 ► System Usability Scale
 ► VAS (0–10)
  Third week after 
registration
  x   
*These variables will be measured in patients from the experimental group only.
EuroQoL- EQ- 5D- 3L, European Quality of Life-5 Dimensions-3 Levels; SAP, Servicio de Atención al Paciente.
Table 1 Continued
 on M
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Therapeutic alliance
The Working Alliance Inventory (WAI)39–41 is a ques-
tionnaire designed to assess the three components of 
the therapeutic alliance defined by Bordin42: therapist–
patient agreement regarding the goals of psychotherapy; 
therapist–patient agreement regarding the tasks to be 
completed in psychotherapy and therapist–patient bond. 
The patient form (WAI- P) and therapist form (WAI- T) of 
the WAI consist of 36 items organised into three subscales 
(Goal, Task, Bond) of 12 items each. The instrument 
has been validated in the Spanish population,43 showing 
excellent reliability of both forms (WAI- P and WAI- T) 
(α=0.96).
Cost–utility and cost-effectiveness analysis
Quality of life
The EuroQoL- EQ- 5D- 3L44 is a standardised instrument 
used as a health outcome measure for economic eval-
uation studies. It consists of five dimensions: mobility, 
self- care, usual activities, pain/discomfort and anxiety/
depression. Each dimension has five levels: no problems, 
slight problems, moderate problems, severe problems 
and extreme problems. The Spanish validation of the 
instrument was carried out by Badia et al.45
Healthcare utilisation
The total number of visits to each healthcare professional 
(ie, oncologist, nursing staff, psychologist, psychiatrist, 
social worker, emergency department) will be assessed 
through the hospital’s SAP.
Medication use and adherence
The Adherence to Refills and Medications Scale (ARMS)46 
was developed to measure medication adherence among 
polypathological patients. It consists of 12 questions: 8 
aimed at assessing the patient’s ability to properly admin-
ister the medication and 4 regarding its correct intake 
based on a four- point Likert scale (range from 1=never to 
4=always), with lower scores indicating better adherence. 
The instrument has been validated in Spanish (ARMS- 
e),47 showing satisfactory psychometric properties. Apart 
from the online questionnaire, a daily medication record 
will be obtained through the monitoring system of the 
ICOnnecta’t application.
Work absenteeism
The number of days of sick leave per patient will be 
assessed through the hospital’s SAP.
Professionals’ salaries
The number of professionals involved in the online treat-
ment or usual care as well as their number of working 
hours per week and their costs will be assessed through 
the SAP.
Infrastructure costs
The costs per user and per month for the development 
and maintenance of the online platform (experimental 
group) and the costs per user and per month for the 
hospital’s infrastructure to guarantee face- to- face visits 
with patients (control group) will be obtained from each 
provider.
Transport costs
An estimate of the cost per patient of using a specific 
type of transport will be obtained through official govern-
mental mobility data from the Barcelona and Girona 
metropolitan areas.
Usability, adherence to and efficacy of the online stepped 
intervention
Emotional well-being
Emotional well- being will be measured weekly through an 
emotional state thermometer based on a Visual Analogue 
Scale (VAS) in the ICOnnecta’t application, only for the 
patients in the experimental group.
Number of clinical cases
The number of clinical cases (those obtaining HADS 
scores>10) will be recorded during treatment.
Waiting-time to begin psychosocial intervention
The period of time from the detection of a clinical case 
(HADS scores >10) to enrolment in the intervention will 
be assessed.
Percentage of resolved cases
The eventual resolution of a clinical case (if patient 
reports HADS <10) will also be measured.
Health education
Scores on health education questionnaires developed by 
our research group will be obtained from the Campus 
of ICOnnecta’t throughout the duration of treatment 
through single measurements per topic. For the control 
group, health knowledge will be assessed using the same 
health education questionnaires in their online format.
Usability
The SUS48 is a 10- item questionnaire that will be used to 
measure the usability of the e- health platform as perceived 
by users in the experimental group.
Satisfaction
The satisfaction of users in the experimental group with 
the platform will be assessed through a VAS (0–10).
Sample size calculation
Sample size was calculated with the support of the GLIM-
MPSE software after having consulted results from the 
previous RCT conducted by van de Berg et al14, which eval-
uated the effectiveness of the BREATH self- management 
platform for patients with BC. To demonstrate a small- 
to- medium effect size of d=0.40 between both arms in 
emotional distress (HADS), 135 patients will be needed 
in each treatment group (power of 80%, significance level 
of 5%). This estimation has considered the site × treat-
ment interaction and assumes a variability scale factor 
of 0.5, given the similarities between centres (they all 
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pertain to the same institution). Allowing for a dropout 
rate of 25%, a total of 338 patients need to be recruited. 
With an annual intake of 1800 BC survivors in the three 
centres during diagnosis and primary oncological treat-
ment, 30% of whom present significant psychological 
distress and 50% of whom would be willing to cooperate, 
the feasibility of the study is guaranteed.
Data management
All data in paper form related to the trial, including 
the health professionals’ paper notes, self- report ques-
tionnaires and informed consent forms, will be securely 
stored in a key- protected cupboard in the principal inves-
tigator’s office at ICO. Regarding online data, these will 
be saved on an encrypted external hard drive stored in 
the same cupboard. All data that support the findings of 
the study will be stored for a minimum of 5 years and 
be available on request from the corresponding author. 
Only authorised researchers directly involved in the study 
will have access to this information.
After obtaining the signed informed consent from 
participants, a unique alphanumeric code will be allo-
cated to each one of them so that analyses can be 
conducted anonymously. The database that links partici-
pants to their codes will be securely stored on a password- 
protected server that will only be accessible to the research 
team. Finally, the information collected through the 
e- health platform will be stored in a secure collaborative 
cloud compliant with the latest version of the European 
General Data Protection Regulation (EC/2016/679). An 
anonymised dataset will be uploaded to the Open Science 
Framework platform (https:// osf. io/), once deleted all 
personal and identifiable information.
Statistical analyses
Descriptive methods will be used to analyse sociodemo-
graphic and clinical variables. Between- group analyses 
will be conducted for baseline differences using Pear-
son’s χ2 test or Fisher’s exact test for categorical data and 
Student’s t- test or the Mann- Whitney U test for contin-
uous variables, depending on the normality of the distri-
bution. The normality of the distribution of the variables 
will be assessed using the Kolmogorov- Smirnov test.
Intention- to- treat analyses will be performed using 
generalised linear mixed models to test the effect of 
interventions (experimental vs control group) on distress 
(HADS scores), post- traumatic stress (PCL-5) and PTGI 
over time (T1–T4), while effect sizes (Hedges’ g) will be 
reported. This procedure considers the multiple depen-
dence between repeated measures while preserving 
analytic power. Later, the effect of the centre × inter-
vention group interaction will also be tested. Finally, the 
influence of age in the results will be assessed, since its 
relationship with digital literacy presents it as a potential 
confounder. Models will be built parsimoniously, with 
maximum likelihood as the estimation method, and 
Little’s Missing Completely At Random (MCAR) test will 
be used to ascertain whether data is missed completely at 
random before deciding if imputation is needed.
For the cost- effectiveness analyses, results from the 
EQ- 5D- 3L will be used to generate the index of life years 
adjusted for quality of life. The cost of each interven-
tion (e- health intervention vs psychosocial treatment as 
usual) will be assessed in terms of the psycho- oncologist’s 
involvement and his/her salary, the number of online 
or face- to- face sessions, infrastructure costs, as well as 
patient’s medication use and adherence, work absen-
teeism and transport costs. Then, a specific analysis of 
cost- effectiveness between the e- health intervention 
and the usual psychosocial treatment will be calculated 
according to the target outcomes of the study: reduction 
of emotional distress, improvement of quality of life, 
improvement of post- traumatic growth and reduction of 
post- traumatic stress.
Analyses will be conducted using SPSS V.24.024 and 
HLM V.7.0.3,49 supported by the expertise of Universitat 
Oberta de Catalunya eHealth Centre in secure health 
information management.
DISCUSSION
This multicentre RCT will assess the clinical efficacy and 
cost- utility of a digital health ecosystem that integrates 
a four- stepped psychosocial programme that is adapted 
to the specific needs of BC survivors and organised 
according to their level of complexity. This is an important 
strength of this study because, to our knowledge, there 
is no previous evidence supporting the efficacy of online 
integrated and stepped interventions in this population.
Regarding the limitations of the study, we must 
acknowledge that it focuses on the specific group of 
patients with BC. As a result, we may encounter difficul-
ties in generalising results to other cancer populations. 
However, efforts by our research team are being made to 
scale the platform to patients with oncohaematological 
diseases, advanced lung cancer and other malignancies in 
different geographical areas.
The design of the study brings along some methodolog-
ical difficulties, especially the risk of a high dropout rate 
over time. To address this challenge, we will include an 
extra 25% of patients in the trial to ensure that the statis-
tical power will be maintained despite patient attrition.
Although the acceptability of online treatments is 
growing11 and recent studies indicate an increase in 
patients’ use of health- related information on internet 
and in participation in interactive communities,50 the age 
of participants and their respective digital literacy may 
condition access to new technologies. As such, we will 
explore the potential confounding effect of age in data 
analyses. In addition, we will provide patients of all ages 
with a technical support service that will be able to train 
them on how to use the platform and solve any techno-
logical issue. In addition, the team has produced video 
tutorials on the correct use of each of the four steps of the 
platform. Access to technological devices could also be a 
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limitation, but we intend to solve that by lending patients 
the necessary devices (ie, webcam, tablet, microphones, 
headphones).
If the findings of this research prove to be positive, 
then the project may lead to critical advances towards 
an integrated model of psychosocial care in cancer that 
could provide fully connected, personalised psychoso-
cial support for the specific needs of each survivor. Such 
advances have the potential to act as a turning point in 
the delivery of patient- centred interventions using new 
technologies and address one of the main challenges 
posed by today’s digital society in serious diseases, such as 
cancer: how to build a therapeutic alliance between citi-
zens and health providers to manage chronic conditions 
in a sustainable way.
Ethics and dissemination
Ethical approval of the study protocol and the informed 
consent forms was received and approved (PR289/19) 
from ‘ICO Hospitalet review board’ (20/02/2020) with 
respect to the scientific content of the protocol and its 
compliance with applicable research and human subjects' 
regulations (see ONCOMMUNITIES informed consent 
on online supplemental material 1. Patients’ participa-
tion is with fully informed written consent, which is revo-
cable at any time.
Findings will be disseminated at a national and interna-
tional level through peer- reviewed journals, reports to the 
funding body, conferences among the scientific commu-
nity, workshops with patients and media press releases.
Twitter Cristian Ochoa- Arnedo @Cristian8apsy
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